In vitro models, in vivo models, and pharmacokinetics: What can we learn from in vitro models?

Clinical Infectious Diseases

Volumn 33, Issue SUPPL. 3, 2001, Pages

  MacGowan, A ^a   Rogers, C ^a   Bowker, K ^a  

^a NATIONAL HEALTH SERVICE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TROVAFLOXACIN;

ANALYTIC METHOD; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL INFECTION; CONCENTRATION RESPONSE; CONFERENCE PAPER; DRUG EFFECT; ERADICATION THERAPY; HUMAN; INFECTION RISK; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; STRAIN DIFFERENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; MODELS, BIOLOGICAL;

EID: 0035884762     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/321850     Document Type: Conference Paper

References (40)

1. Investigation of AUC/MIC ratio as a generic predictor of fluoroquinolone activity against Staphylococcus aureus using trovafloxacin, clinafloxacin, ciprofloxacin, sparfloxacin, levofloxacin and an in vitro model
2. In vitro evaluation of pharmacodynamic outcome parameters for three fluoroquinolones against Streptococcus pneumoniae
3. Moxifloxacin activity against S. pneumoniae in an in vitro dynamic model
4. Pharmacodynamics of moxifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model
5. Activity of moxifloxacin administered once a day against Streptococcus pneumoniae in an in vitro model of infection
6. In vitro pharmacodynamics of moxifloxacin against respiratory tract pathogens
7. Pharmacodynamics of trovafloxacin, ofloxacin and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model
8. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae
9. The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic model
10. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
11. In vitro dynamic models as tools to examine predictors of the antimicrobial effect and to compare pharmacokinetically different quinolones
12. Pharmacodynamics of moxifloxacin
13. In vitro pharmacodynamics of piperacillin-tazobactam and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa
14. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin alone and in combination with rifampicin against methicillin-susceptible and resistant Staphylococcus aureus in an in vitro infection model
15. Pharmacodynamics of trovafloxacin alone and in combination with ampicillin-sulbactam and doxycycline against vancomycin-resistant enterococci in an in vitro model of infection
16. Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection
17. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection
18. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model
19. Pharmacodynamics effect of amikacin, ciprofloxacin and imipenem on growing and non growing Escherichia coli and Pseudomonas aeruginosa
20. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area-under-the-concentration-time curve relationships: Action of ciprofloxacin against Escherichia coli in an in vitro dynamic model
21. Inter and intra quinolone predictors of antimicrobial effect in an in vitro dynamic model: New insight into a widely used concept
22. Twenty four hour area-under-the-concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model
23. Pharmacokinetics and pharmacodynamics of fluoroquinolones
24. Comparison of in vitro pharmacodynamics of once and twice daily ciprofloxacin
25. The effects of Nor A inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in vitro infection model
26. A new approach to in vitro comparisons of antibiotics in dynamic models: Equivalent area-under-the-curve/MIC breakpoints and epi efficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities
27. Antibacterial activity of lomefloxacin in a pharmacokientic in vitro model
28. Variability in antibacterial effect measures used to assess effectiveness of drug regimens in in vitro pharmacodynamic models of infection
29. The activity of gemifloxacin against Streptococcus pneumoniae studied using an in vitro pharmacodynamic model of infection
30. A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative β lactam, aminoglycoside and fluoroquinolone
31. Comparison between antimicrobial pharmacodynamic indices and bacterial killing as described by using the 2hr model
32. In vitro models of infection: Pharmacokinetic/pharmacodynamic correlates
33. In vitro characterisation of fluoroquinolone concentration/MIC, antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin and ciprofloxacin against multiple drug resistant isolates of Streptococcus pneumoniae
34. Pharmacodynamics of moxifloxacin investigated using data from an in vitro model of infection
35. Pharmacodynamics of the fluoroquinolones
36. Pharmacodynamics of intravenous ciprofloxacin in seriously patients
37. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis
38. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
39. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis
40. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance